Lantern Pharma Says FDA Confirms Potential Incorporation Of Spironolactone As Combination Agent In Trial; Plans Ind Amendment Submission & Trial Initiation For Pediatric CNS Cancer Trial In Q1 2026
Author: Benzinga Newsdesk | September 03, 2025 08:51am